Want to join the conversation?
$BAX's sales in Renal for 2Q16 rose by 2% on a reported basis and 4% on constant currency basis. The increase was driven by increased demand globally for continuous renal replacement therapies along with strong sales of peritoneal dialysis products.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.